FOR THE TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA (MCL)\textsuperscript{1}

THE BTK INHIBITOR DEMONSTRATED TO PROVIDE COMPLETE AND SUSTAINED INHIBITION\textsuperscript{1,2}

INDICATION
BRUKINSA\textsuperscript{TM} (zanubrutinib) is a kinase inhibitor indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

IMPORTANT SAFETY INFORMATION
WARNINGS AND PRECAUTIONS
Hemorrhage
Fatal and serious hemorrhagic events have occurred in patients with hematological malignancies treated with BRUKINSA monotherapy. Grade 3 or higher bleeding events including intracranial and gastrointestinal hemorrhage, hematuria and hemothorax have been reported in 2\% of patients treated with BRUKINSA monotherapy. Bleeding events of any grade, including purpura and petechiae, occurred in 50\% of patients treated with BRUKINSA monotherapy.

Please see additional Important Safety Information throughout, and full Prescribing Information.
BRUTON'S TYROSINE KINASE (BTK) PROMOTES THE GROWTH AND SURVIVAL OF MALIGNANT B CELLS

Sustained inhibition of BTK must be maintained at therapeutic concentrations in target tissues.

There are key challenges to inhibiting BTK:

**Challenge**
BTK requires 100% inhibition that is maintained around the clock because it is continuously synthesized.

BTK continues to be overexpressed without inhibition.

BTK is not fully inhibited after introduction of BTK inhibitor.

New BTK is synthesized while drug concentration decreases over its half-life.

BTK inhibitor concentrations need to be sustained across disease-relevant tissues to prevent areas of unchecked disease.

BTK must be selectively targeted to potentially limit adverse effects.

There are key challenges to inhibiting BTK:

**Challenge**
BTK requires 100% inhibition that is maintained around the clock because it is continuously synthesized.

BTK continues to be overexpressed without inhibition.

BTK is not fully inhibited after introduction of BTK inhibitor.

New BTK is synthesized while drug concentration decreases over its half-life.

BTK inhibitor concentrations need to be sustained across disease-relevant tissues to prevent areas of unchecked disease.

BTK must be selectively targeted to potentially limit adverse effects.

**Challenge**

There are key challenges to inhibiting BTK.

**Challenge**

BTK requires 100% inhibition that is maintained around the clock because it is continuously synthesized.

BTK continues to be overexpressed without inhibition.

BTK is not fully inhibited after introduction of BTK inhibitor.

New BTK is synthesized while drug concentration decreases over its half-life.

BTK inhibitor concentrations need to be sustained across disease-relevant tissues to prevent areas of unchecked disease.

BTK must be selectively targeted to potentially limit adverse effects.
BRUKINSA WAS DESIGNED TO COMPLETELY SHUT OFF BTK

Designed to optimize bioavailability, half-life, and selectivity to meet the challenges of BTK inhibition

1 Potent and sustained inhibition
100%, 24-hour inhibition of BTK in PBMCs*1,2

2 Target tissue exposure at therapeutic concentrations
Reaches and occupies BTK in plasma and lymph nodes1,2

3 High affinity for BTK
Minimal off-target binding to other tyrosine kinases including EGFR, FGR, FRK, HER2, HER4, ITK, JAK3, LCK, and TEC8

*The clinical significance of 100% occupancy has not been established.

BTK=Bruton’s tyrosine kinase; PBMCs=peripheral blood mononuclear cells.

IMPORTANT SAFETY INFORMATION (continued)
WARNINGS AND PRECAUTIONS
Hemorrhage (continued)
Bleeding events have occurred in patients with and without concomitant antiplatelet or anticoagulation therapy. Co-administration of BRUKINSA with antiplatelet or anticoagulant medications may further increase the risk of hemorrhage.

Monitor for signs and symptoms of bleeding. Discontinue BRUKINSA if intracranial hemorrhage of any grade occurs. Consider the benefit-risk of withholding BRUKINSA for 3-7 days pre- and post-surgery depending upon the type of surgery and the risk of bleeding.

Infections
Fatal and serious infections (including bacterial, viral, or fungal) and opportunistic infections have occurred in patients with hematological malignancies treated with BRUKINSA monotherapy. Grade 3 or higher infections occurred in 23% of patients treated with BRUKINSA monotherapy. The most common Grade 3 or higher infection was pneumonia. Infections due to hepatitis B virus (HBV) reactivation have occurred.

Please see additional Important Safety Information throughout, and full Prescribing Information.
**EVALUATED GLOBALLY IN 2 TRIALS IN A RANGE OF PATIENTS**

<table>
<thead>
<tr>
<th>Study design</th>
<th>Study 206 (N=86)</th>
<th>Study 003 (N=32)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Description*</td>
<td>Phase 2, open-label, multicenter, single-arm trial</td>
<td>Phase 1/2, open-label, multicenter, single-arm trial</td>
</tr>
<tr>
<td>Setting</td>
<td>Previously treated MCL following at least 1 prior therapy</td>
<td></td>
</tr>
<tr>
<td>Primary endpoint</td>
<td>ORR was assessed by an IRC according to the 2014 Lugano classification for non-Hodgkin lymphoma†</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Baseline patient characteristics</th>
<th>Study 206 (N=86)</th>
<th>Study 003 (N=32)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median age</td>
<td>60.5 years (range: 34-75)</td>
<td>70 years (range: 42-86)</td>
</tr>
<tr>
<td>Caucasian</td>
<td>0%</td>
<td>78%</td>
</tr>
<tr>
<td>Median time since diagnosis</td>
<td>2.5 years</td>
<td>4.5 years</td>
</tr>
<tr>
<td>Median prior anticancer regimens</td>
<td>2 (range: 1-4)</td>
<td>1 (range: 1-4)</td>
</tr>
<tr>
<td>Disease history</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Refractory MCL</td>
<td>52%</td>
<td>25%</td>
</tr>
<tr>
<td>Extranodal disease</td>
<td>71%</td>
<td>78%</td>
</tr>
<tr>
<td>Blastoid variant of MCL</td>
<td>14%</td>
<td>6%</td>
</tr>
<tr>
<td>Prior ASCT</td>
<td>4%</td>
<td>16%</td>
</tr>
<tr>
<td>Most common prior regimens</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CHOP-based</td>
<td>91%</td>
<td>59%</td>
</tr>
<tr>
<td>Rituximab-based</td>
<td>74%</td>
<td>94%</td>
</tr>
<tr>
<td>MIPI score</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Low risk</td>
<td>58%</td>
<td>28%</td>
</tr>
<tr>
<td>Intermediate risk</td>
<td>29%</td>
<td>41%</td>
</tr>
<tr>
<td>High risk</td>
<td>13%</td>
<td>31%</td>
</tr>
</tbody>
</table>

*In Study BGB-3111-206 (Study 206), patients were enrolled in China. In Study BGB-3111-AU-003 (Study 003), patients were enrolled in Australia, New Zealand, Europe, Asia, and the US.
†In Study 206, PET scans were required for response assessment. In Study 003, PET scans were not required for response assessment and the majority of patients were assessed by CT scan.

ASCT=autologous stem cell transplant; CHOP=cyclophosphamide, doxorubicin, vincristine, prednisone; CT=computed tomography; IRC=independent review committee; MCL=mantle cell lymphoma; MIPI=mantle cell lymphoma international prognostic index; ORR=overall response rate; PET=positron emission tomography.
POWERFUL RESPONSES

84% of patients responded to BRUKINSA across both studies\(^1\)

![Graph showing POWERFUL RESPONSES](image)

Median follow-up time was 18.4 months for Study 206 and 18.8 months for Study 003\(^1\)

The efficacy of BRUKINSA was IRC-assessed in 2 clinical trials that included a total of 118 adult patients with MCL who received at least 1 prior therapy. Study 206: N=86, Phase 2, open-label, multicenter, single-arm trial; PET scans were required for response assessment. Study 003: N=32, Phase 1/2, open-label, global, multicenter, single-arm trial; PET scans were not required for response assessment and the majority of patients were assessed by CT scan.

CI=confidence interval; CR=complete response; CT=computed tomography; IRC=independent review committee; ORR=overall response rate; PET=positron emission tomography; PR=partial response.

IMPORTANT SAFETY INFORMATION (continued)

WARNINGS AND PRECAUTIONS

Infections (continued)

Consider prophylaxis for herpes simplex virus, pneumocystis jiroveci pneumonia and other infections according to standard of care in patients who are at increased risk for infections. Monitor and evaluate patients for fever or other signs and symptoms of infection and treat appropriately.

Please see additional Important Safety Information throughout, and full Prescribing Information.
SUSTAINED RESULTS

Most patients responded for more than 18 months\(^1\)

**STUDY 206**

- 19.5 MONTHS Median DOR
  (95% CI: 16.6, NE)

**STUDY 003**

- 18.5 MONTHS Median DOR
  (95% CI: 12.6, NE)

Median follow-up time was 18.4 months for Study 206 and 18.8 months for Study 003\(^1\)

DOR = duration of response; NE = not estimable.

WARNINGS AND PRECAUTIONS (continued)

**Cytopenias**

Grade 3 or 4 cytopenias, including neutropenia (27%), thrombocytopenia (10%) and anemia (8%) based on laboratory measurements, were reported in patients treated with BRUKINSA monotherapy.

Monitor complete blood counts during treatment and treat using growth factor or transfusions, as needed.

**Second Primary Malignancies**

Second primary malignancies, including non-skin carcinoma, have occurred in 9% of patients treated with BRUKINSA monotherapy. The most frequent second primary malignancy was skin cancer (basal cell carcinoma and squamous cell carcinoma of skin), reported in 6% of patients. Advise patients to use sun protection.

**Cardiac Arrhythmias**

Atrial fibrillation and atrial flutter have occurred in 2% of patients treated with BRUKINSA monotherapy. Patients with cardiac risk factors, hypertension, and acute infections may be at increased risk. Grade 3 or higher events were reported in 0.6% of patients treated with BRUKINSA monotherapy. Monitor signs and symptoms for atrial fibrillation and atrial flutter and manage as appropriate.

Please see additional Important Safety Information throughout, and full Prescribing Information.
## DEMONSTRATED SAFETY PROFILE

Combined adverse reactions (ARs) in ≥10% of patients with MCL (N=118)

<table>
<thead>
<tr>
<th>Adverse reactions</th>
<th>All Grades (%)</th>
<th>Grade ≥3 (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Upper respiratory tract infection</td>
<td>39</td>
<td>0</td>
</tr>
<tr>
<td>Neutropenia and Neutrophil count decreased</td>
<td>38</td>
<td>15</td>
</tr>
<tr>
<td>Rash</td>
<td>36</td>
<td>0</td>
</tr>
<tr>
<td>Thrombocytopenia and Platelet count decreased</td>
<td>27</td>
<td>5</td>
</tr>
<tr>
<td>Leukopenia and White blood count decreased</td>
<td>25</td>
<td>5</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>23</td>
<td>0.8</td>
</tr>
<tr>
<td>Pneumonia</td>
<td>15</td>
<td>10</td>
</tr>
<tr>
<td>Anemia and Hemoglobin decreased</td>
<td>14</td>
<td>8</td>
</tr>
<tr>
<td>Musculoskeletal pain</td>
<td>14</td>
<td>3.4</td>
</tr>
<tr>
<td>Hypokalemia</td>
<td>14</td>
<td>1.7</td>
</tr>
<tr>
<td>Bruising</td>
<td>14</td>
<td>0</td>
</tr>
<tr>
<td>Constipation</td>
<td>13</td>
<td>0</td>
</tr>
<tr>
<td>Hypertension</td>
<td>12</td>
<td>3.4</td>
</tr>
<tr>
<td>Cough</td>
<td>12</td>
<td>0</td>
</tr>
<tr>
<td>Hemorrhage</td>
<td>11</td>
<td>3.4</td>
</tr>
<tr>
<td>Urinary tract infection</td>
<td>11</td>
<td>0.8</td>
</tr>
</tbody>
</table>

The most common ARs (≥ 20%; pooled safety population N=629) included neutrophil count decreased (53%), platelet count decreased (39%), upper respiratory tract infection (38%), white blood cell count decreased (30%), hemoglobin decreased (29%), rash (25%), bruising (23%), diarrhea (20%), and cough (20%).
Combined incidence of cardiac arrhythmias in patients with hematologic malignancies (N=629)

<table>
<thead>
<tr>
<th>Adverse reaction</th>
<th>All Grades (%)</th>
<th>Grade ≥3 (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atrial fibrillation and atrial flutter</td>
<td>2.0</td>
<td>0.6</td>
</tr>
</tbody>
</table>

**COMBINED DOSE REDUCTION AND DISCONTINUATION RATES**

Median duration of treatment: 17.5 months (range: 0.2-33.9 months)

Dose reductions due to ARs: 0.8% (1/118) of patients

Discontinuation rate due to ARs: 7% (8/118) of patients

**IMPORTANT SAFETY INFORMATION (continued)**

**WARNINGS AND PRECAUTIONS**

**Embryo-Fetal Toxicity**

Based on findings in animals, BRUKINSA can cause fetal harm when administered to a pregnant woman. Administration of zanubrutinib to pregnant rats during the period of organogenesis caused embryo-fetal toxicity including malformations at exposures that were 5 times higher than those reported in patients at the recommended dose of 160 mg twice daily. Advise women to avoid becoming pregnant while taking BRUKINSA and for at least 1 week after the last dose. Advise men to avoid fathering a child during treatment and for at least 1 week after the last dose.

If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus.

**SPECIFIC POPULATIONS**

**Hepatic Impairment:** The recommended dose of BRUKINSA for patients with severe hepatic impairment is 80 mg orally twice daily.

Please see additional Important Safety Information throughout, and full Prescribing Information.
BRUKINSA DOSING FLEXIBILITY

- BRUKINSA can be taken as 160 mg twice a day or 320 mg once a day\(^1\)
- BRUKINSA can be co-administered with proton pump inhibitors and H2-receptor antagonists\(^1\)
- BRUKINSA can be taken with or without food (advise patients to swallow capsules whole—do not open, break, or chew)\(^1\)
- BRUKINSA was allowed to be co-administered with anticoagulation therapies in clinical trials (as long as INR was ≤1.5 and aPTT ≤1.5 x ULN)\(^10,11\)

BRUKINSA should be taken until disease progression or unacceptable toxicity\(^1\)

**Recommended dose modification for ≥ Grade 3 adverse reactions\(^1\)**

**Event**
- Grade 3 or higher non-hematological toxicities
- Grade 3 febrile neutropenia
- Grade 3 thrombocytopenia with significant bleeding
- Grade 4 neutropenia (lasting more than 10 consecutive days)
- Grade 4 thrombocytopenia (lasting more than 10 consecutive days)

**Dose Modification**
(Starting Dose: 160 mg twice daily or 320 mg once daily)

<table>
<thead>
<tr>
<th>1ST OCCURRENCE</th>
<th>2ND OCCURRENCE</th>
<th>3RD OCCURRENCE</th>
<th>4TH OCCURRENCE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interrupt BRUKINSA</td>
<td>Interrupt BRUKINSA</td>
<td>Interrupt BRUKINSA</td>
<td>Discontinue BRUKINSA</td>
</tr>
<tr>
<td>Once toxicity has resolved to recovery to Grade 1 or lower or baseline: resume at 160 mg twice daily or 320 mg once daily</td>
<td>Once toxicity has resolved to recovery to Grade 1 or lower or baseline: resume at 80 mg twice daily or 160 mg once daily</td>
<td>Once toxicity has resolved to recovery to Grade 1 or lower or baseline: resume at 80 mg once daily</td>
<td></td>
</tr>
</tbody>
</table>

\(\text{aPTT=activated partial thromboplastin time; INR=International Normalized Ratio; ULN=upper limit of normal.}\)

**IMPORTANT SAFETY INFORMATION** (continued)

**DRUG INTERACTIONS**

**CYP3A Inhibitors:** When BRUKINSA is co-administered with a strong CYP3A inhibitor, reduce BRUKINSA dose to 80 mg once daily. For coadministration with a moderate CYP3A inhibitor, reduce BRUKINSA dose to 80 mg twice daily.

**CYP3A Inducers:** Avoid coadministration with moderate or strong CYP3A inducers.

Please see additional Important Safety Information throughout, and full Prescribing Information.
myBeiGene™ PATIENT SUPPORT

Dedicated Oncology Nurse Advocates provide personalized support for each patient’s needs

Simplifying access
- Assists with insurance verification and prior authorization support
- Co-pay as little as $0/prescription for commercially insured patients*
- Bridge supply for insurance coverage delays†
- Free product for uninsured and underinsured patients‡

Educating patients
- Helps provide information about their disease and treatment with BRUKINSA
- Patient and caregiver follow-up support
- Dedicated Oncology Nurse Advocates for practices, patients, and caregivers

Securing support
- Assists patients and caregivers with practical help through connecting patients with advocacy groups and local/national free resources such as:
  - Counseling services
  - Support group information
  - Transportation/lodging assistance

*No patient income requirement. Annual benefit limit of $25,000. Patients are ineligible if prescriptions are payable by any state or other federally funded programs, including, but not limited to, Medicare, Medicaid, VA, or TRICARE, or where prohibited by law. Eligibility criteria and restrictions apply.
†15-day supply of medication (for on-label use only) in case of a coverage delay lasting longer than 5 days. Eligibility criteria and restrictions apply.
‡Certain financial and eligibility criteria apply.


Please see Important Safety Information throughout, and full Prescribing Information.
BRUKINSA is a kinase inhibitor indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

100%, 24-hour inhibition of BTK was maintained in peripheral blood when taken as 160 mg twice a day or 320 mg once a day.1,2

<table>
<thead>
<tr>
<th>STUDY</th>
<th>PET-BASED1</th>
<th>CT-BASED1</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>84% ORR</td>
<td>84% ORR</td>
</tr>
<tr>
<td></td>
<td>59% CR</td>
<td>22% CR</td>
</tr>
<tr>
<td></td>
<td>19.5 mo</td>
<td>18.5 mo</td>
</tr>
<tr>
<td>(95% CI: 74, 91)</td>
<td>(95% CI: 67, 95)</td>
<td>(95% CI: 12.6, NE)</td>
</tr>
</tbody>
</table>

Median follow-up time was 18.4 months for Study 206 and 18.8 months for Study 003.

Zanubrutinib (BRUKINSA™) is included as a second-line therapy option for MCL in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®).12

NCCN PREFERRED

Zanubrutinib is a preferred regimen for short response duration (< expected median PFS) and extended response duration (> expected median PFS) to prior chemoimmunotherapy.

The efficacy of BRUKINSA was IRC-assessed in 2 clinical trials that included a total of 118 adult patients with MCL who received at least 1 prior therapy. Study 206: N=86, Phase 2, open-label, multicenter, single-arm trial; PET scans were required for response assessment. Study 003: N=32, Phase 1/2, open-label, global, multicenter, single-arm trial; PET scans were not required for response assessment and the majority of patients were assessed by CT scan.

BTK=Bruton's tyrosine kinase; CI=confidence interval; CR=complete response; CT=computed tomography; IRC=independent review committee; NCCN=National Comprehensive Cancer Network; NE=not estimable; ORR=overall response rate; PET=positron emission tomography; PFS=progression-free survival.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Hemorrhage

Fatal and serious hemorrhagic events have occurred in patients with hematological malignancies treated with BRUKINSA monotherapy. Grade 3 or higher bleeding events including intracranial and gastrointestinal hemorrhage, hematuria and hemothorax have been reported in 2% of patients treated with BRUKINSA monotherapy. Bleeding events of any grade, including purpura and petechiae, occurred in 50% of patients treated with BRUKINSA monotherapy.

BRUKINSA, myBeiGene, the myBeiGene logo, and BeiGene are trademarks owned by BeiGene, Ltd. © BeiGene, Ltd. 2020 All Rights Reserved. 0919-BRU-PRC-034 03/2020

Please see additional Important Safety Information throughout, and full Prescribing Information.